Tissue and plasma-based mechanisms of resistance to first-line osimertinib in EGFR-mutant NSCLC: A multi-institutional cohort.Zofia Piotrowska, Catherine A. Shu, Matthew Guo et al.|Journal of Clinical Oncology|2023Cited by 9
First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohortsSaurav D. Haldar, Neeha Zaidi, Amanda L. Huff et al.|Cancer Discovery|2026Cited by 1